Results 101 to 110 of about 12,253 (284)

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

open access: yesMolecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy   +10 more
wiley   +1 more source

Modeling Mixed-critical Systems in Real-time BIP

open access: yes, 2013
International audienceThe proliferation of multi- and manycores creates an important design problem: the design and verification for mixed-criticality constraints in timing and safety, taking into account the resource sharing and hardware faults.
Bozga, Marius   +3 more
core   +1 more source

Clinical performance of the urine‐based TERT promoter AbsoluteQ Digital PCR for non‐invasive detection of bladder cancer

open access: yesMolecular Oncology, EarlyView.
A urine‐based digital PCR assay targeting two hotspot TERT promoter variants detected bladder cancer with high sensitivity and no false positives in this case–control cohort. The streamlined AbsoluteQ workflow outperformed Sanger sequencing and supports non‐invasive molecular testing for bladder cancer detection.
Anna Nykel   +12 more
wiley   +1 more source

Replica-Aware Co-Scheduling for Mixed-Criticality.

open access: yes, 2017
Cross-layer fault-tolerance solutions are the key to effectively and efficiently increase the reliability in future safety-critical real-time systems. Replicated software execution with hardware support for error detection is a cross-layer approach that exploits future many-core platforms to increase reliability without resorting to redundancy in ...
Rambo, Eberle A., Ernst, Rolf
openaire   +3 more sources

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

End-to-end delay analysis for mixed-criticality WirelessHART networks

open access: yes, 2015
WirelessHART, as a robust and reliable wireless protocol, has been widely-used in industrial wireless sensoractuator networks. Its real-time performance has been extensively studied, but limited to the single criticality case.
Jin X(金曦)   +2 more
core  

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

An analytics-driven optimization framework for nurse scheduling under uncertainty

open access: yesHealthcare Analytics
Nurse scheduling in hospitals is a complex optimization problem influenced by uncertain staff absences, regulatory constraints, and the need to ensure fair workload distribution.
Hadil Chorfi   +3 more
doaj   +1 more source

Scheduling Multi-Periodic Mixed-Criticality DAGs on Multi-Core Architectures

open access: yes, 2018
International audienceThanks to Mixed-Criticality (MC) scheduling, high and low-criticality tasks can share the same execution platform, improving considerably the usage of computation resources.
Medina, Roberto   +5 more
core   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

open access: yesMolecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy